Vaccin à base de cellules dendritiques
Dendritic Cell Vaccines: Personalised Cancer Immunotherapy
In line with our vision, we strive to offer individualised care that is aligned with the unique needs of each patient. To this end, we offer a technique at the cutting edge of oncology: dendritic cell vaccines. This personalised treatment uses your own immune cells to fight cancer, opening up a new avenue in the world of targeted therapies.
The Key Role of Dendritic Cells
Dendritic cells are key components of the immune system. Their main role is to act as messengers between innate and adaptive immune cells. In short, they 'present' antigens to T cells, triggering a targeted immune response against pathogens or tumour cells.
The Dendritic Cell Vaccine Process
1. Collection and isolation : Dendritic cells are collected directly from your own blood, guaranteeing perfect compatibility and minimising the risk of adverse reactions.
2. Laboratory activation: The isolated cells are then exposed to antigens specific to the cancer cells you carry. This enables precise, targeted activation of the dendritic cells.
3. Reinjection into the patient : The activated dendritic cells are reinjected into your body. They then travel to the lymph nodes and trigger a powerful immune response against the cancer cells.
4. Monitoring and evaluation: A series of checks and evaluations are carried out to measure the success of the therapy and adjust the treatment as necessary.
The Importance of Individualisation
This treatment fits perfectly with our philosophy of personalised healthcare. By using your own cells, we can create a treatment that is specifically tailored to your biological profile, greatly increasing the chances of success.
Benefits for Cancer
-Targeted and effective: Because it uses antigens specific to your cancer cells, this vaccine is incredibly targeted.
- High tolerance: Using your own cells reduces the risk of complications and side effects.
Conclusion
Active immunotherapy, such as DCV, combines well with other treatments such as passive immunotherapy, like CIK-Cells therapy, which mobilises the patient's immune system. Immunotherapies with CIK and DCV constitute an advanced combined therapy, as they work on very different principles, contributing to a broad and complex immune response against cancer. Combinations with ozone therapy and the IV therapies we offer are also possible. There is also the possibility of combining with chemotherapy that patients may already be undergoing. This combined approach is not only compatible, but also advantageous. Indeed, current research indicates that combining several therapeutic methods increases the success rate, offering a global strategy for the fight against cancer.
Clearly, given the complexity and importance of these therapies, they need to be discussed in consultation and strictly monitored.